Lilly’s empagliflozin accepted for marketing by EMA

Lilly has announced its empagliflozin type 2 diabetes treatment developed alongside Boehringer Ingelheim has been accepted for marketing authorization by the European Medicines Agency.

The pharmaceutical company has confirmed the investigational compound was given the green light following the submission of a New Drug Application to the US Food and Drug Administration.

Lilly revealed the acceptance of the marketing authorisation application marks the launch of a review process in the European Union for the potential oral treatment for type 2 diabetes.

The empagliflozin is a member of the sodium glucose co-transporter-2 class of drugs that are currently being investigated for the reduction of blood glucose levels among patients with this branch of the condition.

Professor Klaus Dugi, corporate senior vice-president of Boehringer Ingelheim, said: "More than 300 million people worldwide live with type 2 diabetes mellitus and varied approaches to treating this condition are needed to help these patients better manage their condition."